Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00. Following the sale, the insider now owns 42,246 shares in the company, valued at $2,116,102.14. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Price Performance

RxSight stock traded down $0.65 during mid-day trading on Tuesday, hitting $49.61. The company’s stock had a trading volume of 211,049 shares, compared to its average volume of 476,145. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54. The business has a 50 day moving average price of $51.99 and a 200-day moving average price of $53.88. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -39.37 and a beta of 1.20.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm’s quarterly revenue was up 67.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) earnings per share. On average, equities research analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Oppenheimer lowered their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. BTIG Research upped their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus reduced their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight has an average rating of “Buy” and a consensus target price of $60.14.

Institutional Trading of RxSight

A number of institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP acquired a new stake in shares of RxSight in the 1st quarter worth about $1,929,000. Principal Financial Group Inc. raised its holdings in RxSight by 298.5% during the 1st quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock worth $1,802,000 after purchasing an additional 26,164 shares during the last quarter. Baillie Gifford & Co. bought a new stake in RxSight during the 1st quarter worth approximately $3,429,000. M&G Plc acquired a new stake in shares of RxSight in the 1st quarter valued at approximately $7,354,000. Finally, Inspire Investing LLC bought a new position in shares of RxSight in the first quarter worth $917,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.